Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Int J Gen Med ; 15: 6765-6773, 2022.
Article in English | MEDLINE | ID: mdl-36039305

ABSTRACT

Purpose: The clinical presentation of iron deficiency is not well understood. We aimed to identify the clinical manifestations of iron deficiency without anemia in women. Patients and Methods: We conducted a retrospective cohort study of women who visited the general internal medicine outpatient department of a university hospital in Japan between 2016 and 2022. Women who were prescribed iron supplements were included in the study. Anemia was defined as hemoglobin levels below 12 g/dl. Iron deficiency was defined as serum ferritin levels < 30.0 µg/l. The primary outcome was the difference in symptoms between patients with iron deficiency with and without anemia. The secondary outcome was the ratio of symptom, hemoglobin, and serum ferritin improvement (levels > 30.0 µg/l after treatment), comparing the measurements at the beginning and after supplementation. Results: A total of 147 women were included in the final analysis. There were no significant differences in the initial symptoms and the ratio of symptom improvement between the groups. Compared to patients with iron deficiency anemia, patients with iron deficiency without anemia had high initial serum ferritin levels (14.8 vs 7.1 µg/l, p<0.001), and hemoglobin (13.2 vs 9.9 g/dl, p<0.001). Iron supplements significantly improved the serum ferritin level in two groups and the hemoglobin in iron deficiency anemia. After treatment, iron deficiency without anemia still had high serum ferritin levels (37.7 vs 28.2 µg/l, p=0.017) and hemoglobin (13.3 vs 12.3 g/dl, p < 0.001). Conclusion: There were no differences in any of the investigated symptoms and the ratio of the symptom improvement depending on the anemic state in iron deficiency. After iron supplementation, the serum ferritin levels in the iron deficiency without anemia group improved. Hemoglobin and serum ferritin in iron deficiency without anemia were still highly comparable to that of iron deficiency anemia.

2.
BMC Psychiatry ; 19(1): 394, 2019 12 12.
Article in English | MEDLINE | ID: mdl-31830951

ABSTRACT

BACKGROUND: Somatization is regarded as psychological or emotional distress in the form of physical symptoms that are otherwise medically unexplained. CASE PRESENTATION: We report a case of a patient with a somatic symptom disorder (SSD) and depression who was later diagnosed with anterior cutaneous nerve entrapment syndrome (ACNES) when Carnett's test was positive and block anesthesia using trigger point injections dramatically improved the symptom of abdominal pain. CONCLUSION: We concluded that the differentiation of SSDs, such as psychogenic pain, from ACNES is very difficult. Psychiatrists should be aware of this syndrome.


Subject(s)
Medically Unexplained Symptoms , Nerve Compression Syndromes/diagnosis , Nerve Compression Syndromes/psychology , Abdominal Pain/diagnosis , Abdominal Pain/etiology , Abdominal Pain/psychology , Adolescent , Diagnosis, Differential , Female , Humans , Mental Disorders/complications , Mental Disorders/diagnosis , Mental Disorders/psychology
3.
BMJ Case Rep ; 20182018 Sep 19.
Article in English | MEDLINE | ID: mdl-30232206

ABSTRACT

Microangiopathic haemolytic anaemia with thrombocytopenia, called pseudo-thrombotic microangiopathy (TMA), is a clinically important complication in patients with vitamin B12 deficiency. We herein present a case of an 80-year-old woman with pseudo-TMA after gastrectomy. She was initially suspected with thrombotic thrombocytopenic purpura based on rapid progression of anaemia with schistocytes and thrombocytopenia; however, her anaemia and thrombocytopenia were improved by vitamin B12 supplementation alone, with a single session of plasma exchange. Vitamin B12 deficiency was finally confirmed by low vitamin B12 levels from the patient's initial blood sample. In addition, normal ADAMTS13 activity was proven, lowering the likelihood of thrombotic thrombocytopenic purpura. Therefore, this patient was diagnosed with pseudo-TMA caused by vitamin B12 deficiency. Pseudo-TMA can occur in patients with vitamin B12 deficiency post-gastrectomy.


Subject(s)
Anemia, Hemolytic/diagnosis , Gastrectomy/adverse effects , Thrombotic Microangiopathies/diagnosis , Vitamin B 12 Deficiency/complications , ADAMTS13 Protein/drug effects , Administration, Intravenous , Aged, 80 and over , Anemia, Hemolytic/etiology , Asian People/ethnology , Diagnosis, Differential , Female , Humans , Plasmapheresis/methods , Thrombotic Microangiopathies/etiology , Treatment Outcome , Vitamin B 12/administration & dosage , Vitamin B 12/therapeutic use
4.
Article in English | MEDLINE | ID: mdl-29462674

ABSTRACT

Lysophosphatidic acid (LPA) is a bioactive phospholipid that induces diverse biological responses. Recently, we found that LPA ameliorates NSAIDs-induced gastric ulcer in mice. Here, we quantified LPA in 21 medicinal herbs used for treatment of gastrointestinal (GI) disorders. We found that half of them contained LPA at relatively high levels (40-240 µg/g) compared to soybean seed powder (4.6 µg/g), which we previously identified as an LPA-rich food. The LPA in peony (Paeonia lactiflora) root powder is highly concentrated in the lipid fraction that ameliorates indomethacin-induced gastric ulcer in mice. Synthetic 18:1 LPA, peony root LPA and peony root lipid enhanced prostaglandin E2 production in a gastric cancer cell line, MKN74 cells that express LPA2 abundantly. These materials also prevented indomethacin-induced cell death and stimulated the proliferation of MKN74 cells. We found that LPA was present in stomach fluids at 2.4 µM, which is an effective LPA concentration for inducing a cellular response in vitro. These results indicated that LPA is one of the active components of medicinal herbs for the treatment of GI disorder and that orally administered LPA-rich herbs may augment the protective actions of endogenous LPA on gastric mucosa.


Subject(s)
Dinoprostone/metabolism , Indomethacin/adverse effects , Lysophospholipids/therapeutic use , Plants, Medicinal/chemistry , Animals , Cell Death/drug effects , Cell Proliferation/drug effects , Mice , Signal Transduction/drug effects , Stomach Ulcer/chemically induced , Stomach Ulcer/drug therapy , Stomach Ulcer/metabolism
5.
J Sci Food Agric ; 96(11): 3717-22, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26676315

ABSTRACT

BACKGROUND: Metabolic syndrome is a major risk factor for a variety of obesity-related diseases. Recently, the effects of functional foods have been investigated on lipid metabolism as a means to reduce lipid content in the blood, liver and adipose tissues associated with carnitine O-palmitoyltransferase (CPT) activity. Acanthopanax senticosus (Rupr. et Maxim) Harms (AS) is a medicinal herb possessing a wide spectra of functions including antioxidant, anti-inflammatory and anti-fatigue actions. Despite much research being focused on the cortical roots of AS, little information is available regarding its leaves, which are also expected to promote human health, for example by improving abnormal lipid metabolism. Here, we explored whether AS leaves affect lipid metabolism in mice fed a high-fat diet. RESULTS: The administration of AS to BALB/c mice fed a high-fat diet significantly decreased plasma triglycerides (TG). CPT activity in the liver of these mice was significantly enhanced by AS treatment. CONCLUSION: These findings indicate that AS leaves have the potential to alleviate increase in plasma TG levels due to high-fat diet intake in mice, possibly by increasing mitochondrial fatty acid ß-oxidation, especially via CPT activation. Consequently, daily intake of AS leaves could promote beneficial health effects including the prevention of metabolic syndrome. © 2015 Society of Chemical Industry.


Subject(s)
Diet, High-Fat , Eleutherococcus , Hyperlipidemias/metabolism , Hypolipidemic Agents/pharmacology , Liver/drug effects , Plant Extracts/pharmacology , Triglycerides/blood , Animals , Carnitine O-Palmitoyltransferase/metabolism , Hyperlipidemias/blood , Hyperlipidemias/etiology , Hyperlipidemias/prevention & control , Hypolipidemic Agents/therapeutic use , Lipid Metabolism , Liver/metabolism , Male , Mice, Inbred BALB C , Mitochondria/metabolism , Phytotherapy , Plant Extracts/therapeutic use , Plant Leaves
SELECTION OF CITATIONS
SEARCH DETAIL